Specialty Pharmacy

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This medication is the first precision therapy approved to treat a genomically defined population of patients with GIST, according to Blueprint Medicines.

Top news of the day from across the health care landscape.

Micafungin injection is the first antifungal drug approved in the United States specifically for pediatric patients younger than 4 years of age with invasive candidiasis.

Secukinumab provided early and sustained resolution of enthesitis in patients with psoriatic arthritis based on post hoc analysis pooled data from the FUTURE trial.

Officials with the FDA have approved pembrolizumab (Keytruda, Merck) for the treatment of certain patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer.

Top news of the day from across the health care landscape.

Study seeks to determine how HIV avoids the zinc-finger antiviral protein and how it binds the RNA.

There are some basic tips or tricks to getting the most out of your insurance plan and to maintain the care patients are accustomed to.

Manufacturers have selected AllianceRx Walgreens as their limited distribution drug partner for drugs that treat conditions such as myelofibrosis, cystic fibrosis, and non-metastatic castration-resistant prostate cancer.

An effective treatment plan for squamous cell carcinoma best undertaken by a group of practitioners.

Top news of the day from across the health care landscape.

Since 2004, the FDA has approved different treatments for advanced prostate cancer, adding almost 2-3 indications per year for the past 15 years.

A study suggests that even brief art-making interventions can be beneficial for stressed caregivers of patients with cancer.

Top news of the day from across the health care landscape.

Researchers investigate whether on-demand pre-exposure prophylaxis was similarly effective among individuals with lower exposure to HIV risk.

According to the study authors, such “anti-austerity agents” represent a promising approach to cancer chemotherapy.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times

By entering clinical and disease characteristics into a learning algorithm, researchers were able to create an efficacy prediction for CDK inhibitors.

The study led to insight on the process of tuberculosis bacillus infection as well as a potential drug treatment.

Top news of the day from across the health care landscape.

Abemaciclib is a potent oral cyclin-dependent kinase 4/6 inhibitor that has previously demonstrated statistically significant improvement in PFS and ORR in combination with endocrine therapy.

Rita Nanda, MD, explains how researchers are aiming to make immunologically silent tumors more inflamed. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.

Study findings presented at the American Society of Nephrology’s Kidney Week 2019 suggest a link between chronic use of proton pump inhibitors and progression of kidney function decline in chronic kidney disease.

From newsworthy moments to groundbreaking research, these are the most popular articles published on Pharmacy Times® during 2019.

Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and Merck) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Individuals with HIV have more QT interval variability than those without the disease, which may lead to the increased risk of sudden cardiac death.

Researchers may have found a way to stop the driving force at a molecular level behind acute lymphoblastic leukemia.